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Abstract
Branched‐chain amino acids (BCAA: leucine, isoleucine and valine) are essential
amino acids implicated in glucose metabolism and maintenance of correct brain
function. Elevated BCAA levels can promote an inflammatory response in periph-
eral blood mononuclear cells. However, there are no studies analysing the direct
effects of BCAA on endothelial cells (ECs) and its possible modulation of vascular
function. In vitro and ex vivo studies were performed in human ECs and aorta
from male C57BL/6J mice, respectively. In ECs, BCAA (6 mmol/L) increased eNOS
expression, reactive oxygen species production by mitochondria and NADPH oxi-
dases, peroxynitrite formation and nitrotyrosine expression. Moreover, BCAA
induced pro‐inflammatory responses through the transcription factor NF‐κB that
resulted in the release of intracellular adhesion molecule‐1 and E‐selectin confer-
ring endothelial activation and adhesion capacity to inflammatory cells. Pharmaco-
logical inhibition of mTORC1 intracellular signalling pathway decreased BCAA‐
induced pro‐oxidant and pro‐inflammatory effects in ECs. In isolated murine aorta,
BCAA elicited vasoconstrictor responses, particularly in pre‐contracted vessels and
after NO synthase blockade, and triggered endothelial dysfunction, effects that
were inhibited by different antioxidants, further demonstrating the potential of
BCAA to induce oxidative stress with functional impact. In summary, we demon-
strate that elevated BCAA levels generate inflammation and oxidative stress in
ECs, thereby facilitating inflammatory cells adhesion and endothelial dysfunction.
This might contribute to the increased cardiovascular risk observed in patients
with elevated BCAA blood levels.
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1 | INTRODUCTION
Branched‐chain amino acids (BCAA: leucine, isoleucine and
valine) are essential amino acids which are important compo-
nents of proteins in human skeletal muscles.1 BCAA also modu-
late glucose metabolism2 and contribute to the maintenance of
correct brain function.3 Therefore, BCAA are used as supple-
ments in states of malnutrition to prevent muscular cachexia in
critical and oncological patients.4 In addition, these amino acids
are commonly used at high doses as nutritional supplements to
potentially improve mental and physical performance and with
the purpose of muscle building.5,6 However, there are not solid
performed studies about the potential toxicity of excessive or
chronic BCAA supplementation.
Increased BCAA plasma concentrations have been found in
several pathological conditions such as Maple syrup urine dis-
ease (MSUD)7 and type 2 diabetes (T2DM) and obesity.8-10
Importantly, highly elevated BCAA blood concentrations in
MSUD patients are responsible for neurological damage,11 and
in T2DM and obesity, elevated BCAA blood concentrations are
associated with insulin resistance10,12 and were suggested as
important predictors of future diabetes and positively associ-
ated with enhanced cardiovascular risk.13,14 In fact, some
authors proposed BCAA as biomarkers for vascular complica-
tions such as subclinical atherosclerosis or coronary artery dis-
ease.15 However, the mechanisms involved are rather poorly
understood.
Chronic low‐grade inflammation16,17 and oxidative stress18,19
are major pathophysiological mechanisms involved in T2DM, obe-
sity and atherosclerosis leading to insulin resistance, endothelial
dysfunction and micro‐ and macro‐vascular complications.
Increased reactive oxygen species (ROS) generation induces
endothelial dysfunction by impairing the bioactivity of endothelial
NO and promotes leucocyte adhesion, inflammation, thrombosis
and smooth muscle cell proliferation—all processes that exacer-
bate atherosclerosis. NADPH oxidase and mitochondria are key
sources of vascular oxidative stress involved in endothelial dys-
function in several cardiovascular pathologies.20,21 We recently
demonstrated that in cultured human peripheral blood mononu-
clear cells (PBMC), high BCAA concentration promotes oxidative
stress from NADPH oxidase and mitochondria, the release of
pro‐inflammatory cytokines mediated by the activation of the
nuclear transcription factor‐κB (NF‐κB) and the migration of
PBMC via the activation of the mammalian target of rapamycin
(mTORC1) axis.22 However, whether this also occurs in endothe-
lial cells (ECs), and whether it might contribute to endothelial
dysfunction, is unknown.
In this study, we hypothesized that BCAA‐derived ROS and
inflammation might be important contributors of abnormal vascular
function. Therefore, we evaluated the direct effects of high BCAA
levels on ECs and aorta and the possible mechanisms involved in such
effects with particular emphasis on ROS generation and inflammation.
2 | MATERIALS AND METHODS
2.1 | Cell culture
Human vascular ECs were isolated from the macroscopically
healthy part of intact saphenous veins harvested from patients
undergoing high ligation of varicose veins as described.23 The
veins were rinsed with PBS 1×, opened longitudinally to expose
the endothelium and put it in direct contact with enzyme solution
containing 1 mg/mL of collagenase type I (Gibco) for 30 minutes
at 37°C in a humidified atmosphere of CO2 (5%). After the diges-
tion step, the upper face of endothelium was scraped to detach
the ECs. Then, cells were centrifuged and seeded on gelatin 0.5%
coated 6‐well dishes and maintained in DMEM‐F12 medium sup-
plemented with FBS (20%), endothelial cells growth factor (ECGF,
30 μg/mL) and heparin (0.1 mg/mL) all from Sigma‐Aldrich (Sigma
Chemical Co., St. Louis, MO, USA) in a 37°C, 5% CO2 humidified
incubator. After 5‐7 days in DMEM‐F12, several cell colonies grew
and were selected with human CD31 antibody bound to Dyn-
abeads (Invitrogen, Life Technologies, Carlsbad, CA, USA). Cell cul-
tures were used between passages 2 and 5. ECs were stimulated
with BCAA (0.2‐12 mmol/L or 6 mmol/L) for 1 hour in the pres-
ence or absence of different inhibitors (see Section 3) added
30 minutes before stimulation. Control cells were not exposed to
stimuli or inhibitors.
2.2 | Western blot
Whole cell lysates were harvested in lysis buffer containing:
25 mmol/L Tris‐HCl pH 7.5, 150 mmol/L NaCl, 0.1% (v/v) sodium
dodecyl sulphate (SDS), 1% Nonidet‐P40 (NP‐40), a protease inhi-
bitor cocktail (Roche Applied Science, Barcelona, Spain) and a mix
of phosphatase inhibitors (1 mmol/L orthovanadate, 20 mmol/L β‐
glycerophosphate, 10 mmol/L NaF from Sigma‐Aldrich). Protein
content was determined with BCA protein assay reagent (Pierce,
Rockford, IL, USA), using bovine serum albumin (BSA, Sigma‐
Aldrich., (Sigma Chemical Co., St. Louis, MO, USA) as standard.
Lysates (30‐50 μg per lane) were separated by 10% SDS‐PAGE,
transferred to nitrocellulose membranes (Bio‐Rad Laboratories,
Hercules, CA, USA), and incubated overnight with monoclonal pri-
mary antibodies against p‐mTOR (Ser2448), mTOR, p‐Akt (Thr
308), p‐AMPK (Thr172), p‐p65 (Ser536) (all 1/500; Cell Signalling,
Boston, MA, USA), eNOS (1/500, BD Transduction Laboratories)
and GAPDH (1/1000; Merck‐Millipore, Corporation, Billerica, MA,
USA)). Appropriate HRP‐labelled anti‐mouse (1/5000, DAKO
Cytomation) or anti‐rabbit (1/5000, Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA, USA) secondary antibodies were subsequently
used for 1 hour at room temperature. The signal was detected
using Luminata Forte (Merck‐Millipore Corporation, Billerica, MA,
USA) with an ImageQuant LAS 4000 gel documentation system
(GE Healthcare, Little Chalfont, UK) and normalized to GAPDH
and expressed as fold increase over control.
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2.3 | RNA analysis
Cells were harvested in TRIzol (Life Technologies Inc., Gaithersburg,
MD, USA) to obtain total RNA, which was reverse transcribed using a
high capacity cDNA RT kit (Applied Biosystems CA, USA). Quantita-
tive PCR (qPCR) was performed in 7500 Fast ABI System (Life
Technologies Inc., Carlsbad, CA, USA) using commercial human
Taqman assays (Thermo Fisher Scientific, Waltham, MA USA):
ICAM‐1: Hs00164932_m1; E‐Selectin: Hs00174057_m1; NOX‐1:
Hs00246589_m1; NOX‐2: Hs00166163_m1; iNOS: Hs01110250_m1,
eNOS: Hs01574665_m1 and 18S rRNA: 4310893E. Data were
expressed as fold increase over control.
2.4 | NADPH oxidase activity assay
The O2
·− production generated by NADPH oxidase activity was
determined by a chemiluminescence assay, as described.22 Briefly,
ECs were rinsed with PBS and harvested in phosphate buffer
(50 mmol/L KH2PO4, 1 mmol/L EGTA, 150 mmol/L sucrose, pH 7.4).
The reaction was started by the addition of a lucigenin mixture
(5 μmol/L) and NADPH (100 μmol/L) (Sigma‐Aldrich) to the protein
sample in a final volume of 250 μL. Chemiluminescence was deter-
mined every 2.4 seconds for 3 minutes in a microtiter plate lumi-
nometer (Enspire Perkin Elmer). Basal activity in the absence of
NADPH was subtracted from each reading, normalized to protein
concentration and expressed as fold increase over control.
2.5 | Detection of intracellular mitochondrial
superoxide production
For quantifying the production of mitochondrial O2
·−, ECs were incu-
bated with Mitosox Red (0.5 μmol/L; Life Technologies Inc.) for
30 minutes in the dark. The fluorescence intensity was measured
with a microtiter plate fluorimeter (Enspire Perkin Elmer) and each
reading was normalized to protein concentration. Data were
expressed as fold increase over control. Additionally, ECs plated in
coverslips were incubated with Mitosox, counterstained with DAPI
(Sigma) and visualized with a confocal microscope (Leica TCS SP2,
40× objective), λexcitation = 510 and λemission = 580 nm, using the
same imaging settings in each case.
2.6 | DNA binding assay
DNA binding assay was performed as described by Li et al24 with
minor modifications. Oligonucleotides for NF‐κB (0.125 pmol/μL) and
NF‐κB complementary sequences (50 nmol/L) were synthesized by
Invitrogen. Primary antibodies were used for p65 (1/200, Cell
Signalling, Boston, MA, USA) detection. A donkey anti‐rabbit Alexa
488 (1/2000, Life Technology) secondary antibody was used to
detect it in a microtiter plate fluorimeter (Enspire, Perkin Elmer)
(λexcitation = 495 and λemission = 519 nm). Data were represented as
fluorescence intensity and expressed as fold increase over control.
2.7 | Cells adhesion assay
ECs were plated in 96‐well plates (1 × 104 cells/well) and stimulated
with BCAA (6 mmol/L, 1 hour) in the presence or absence of different
inhibitors (see Section 3) for 30 minutes. On the other hand, PBMC
(1 × 105/well) were stained with 5 μmol/L calcein‐AM (Sigma Aldrich)
and coincubated with ECs for 30 minutes. Non‐adherent cells were
removed and adhered PBMCs were harvested in 0.1% SDS and fluo-
rescence from each well was measured at λexcitation = 485 nm and
λemission = 530 nm. The adhesion capacity was calculated as relative
fluorescence/protein and expressed as fold increase over control.
2.8 | Vascular reactivity studies
Ex vivo experiments were performed in intact aorta from 3‐month‐
old male C57BL/6J mice. All experimental procedures were
approved by the Ethical Committee of Research of the Universidad
Autónoma de Madrid and Dirección General de Medio Ambiente,
Comunidad de Madrid, Spain (PROEX 345/14). Animals were taken
care of and used according to the Spanish Policy for Animal Pro-
tection RD53/2013, which meets the European Union Directive
2010/63/UE on the protection of animals used for experimental
and other scientific purposes and experiments were conducted in
accordance with the National Institutes of Health (NIH) Guide for
the Care and Use of Laboratory Animals. The animals were killed
with CO2.
Vascular reactivity was studied in a wire myograph by isometric
tension recording. After a 30‐minutes equilibration period in oxy-
genated Krebs Henseleit solution (KHS) at 37°C and pH 7.4, seg-
ments were stretched to their optimal lumen diameter for active
tension development. This was determined based on the internal
circumference/wall tension ratio of the segments by setting their
internal circumference (Lo) to 90% of what the vessels would have
if they were exposed to a passive tension equivalent to that pro-
duced by a transmural pressure of 100 mm Hg. Contractility of the
segments was tested by an initial exposure to a high K+ solution
(K+‐KHS, 120 mmol/L). The presence of endothelium was deter-
mined by the ability of 10 μmol/L acetylcholine to relax arteries
pre‐contracted with phenylephrine at ∼50% K+‐KHS contraction.
Thereafter, concentration‐response curves to BCAA (0.2‐10 mmol/L)
with or without pre‐contraction with phenylephrine (0.3 μmol/L),
were performed. The effects of gp91dstat (5 μmol/L), ML171
(0.5 μmol/L) and mito‐TEMPO (0.5 μmol/L) were analysed by their
addition 30 minutes before the BCAA concentration‐response
curves.
In some experiments, mouse aortic segments were pre‐incu-
bated in the organ bath with N‐nitro‐L‐arginine methyl ester (L‐
NAME, 0.1 mmol/L) in the absence or presence of gp91dstat,
ML171, mito‐TEMPO or celecoxib (1 μmol/L) before the BCAA con-
centration‐response curves. These segments were not pre‐con-
tracted with phenylephrine. These drugs were added 30 minutes
before L‐NAME.
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To demonstrate a possible direct effect of BCAA on vascular
smooth muscle cells we performed experiments where the
endothelium was mechanically removed. Concentration‐response
curves to BCAA in phenylephrine pre‐contracted vessels or in
arteries incubated or not with L‐NAME were performed as
described above.
In another set of experiments, aortic segments were exposed to
BCAA (6 mmol/L) in the absence or presence of gp91dstat, ML171
and mito‐TEMPO in DMEM‐F12 Ham supplemented with 1% FBS
and antibiotics (100 U/mL of penicilin and 100 mg/mL of strepto-
mycin) for 24 hours, 37°C. Afterwards, concentration‐response
curves to acetylcholine (1‐10 μmol/L), diethylamine NONOate (DEA‐
NO, 1‐10 μmol/L) and phenylephrine (1‐30 μmol/L) were performed
in each segment. Control arteries were not exposed to stimuli and
they were incubated in the same culture conditions.
Vasoconstrictor responses were expressed as mN/mm. BCAA‐
induced contractile responses were measured either from the basal
level or after pre‐contraction with phenylephrine. Vasodilator
responses were expressed as a percentage of the previous tone gen-
erated by phenylephrine.
2.9 | Immunohistochemistry
OCT‐embedded aortic segments were stained using standard histol-
ogy procedures. Immunostaining was carried out in 3‐μm‐thick tissue
sections and fixed using phosphate‐buffered 4% paraformaldehyde.
Endogenous peroxidase was blocked and aorta sections were incu-
bated with the primary antibody (3‐Nitrotyrosin, 1/1000; Abcam,
Cambridge, UK) overnight at 4°C. After washing, slides were treated
with the corresponding anti‐IgG biotinylated‐conjugated secondary
antibody (Amersham Bioscience, Amersham, UK) followed by the avi-
din‐biotin‐peroxidase complex, and 3,3′‐diaminobenzidine as chro-
mogen (Dako Diagnosticos S.A.). Sections were counterstained with
Carazzi's haematoxylin and mounted with DPX. The specificity was
checked by omission of primary antibodies and use of non‐immune
sera. Images were obtained with the Nikon Eclipse E400 microscope
and analysed by Image Pro‐plus (Media Cybernetics, Inc., Rockville,
MD). All samples were evaluated in a blinded manner. For each
mouse, the mean score value was obtained by evaluating 4 different
high‐power fields (40×) per section.
2.10 | Fluorimetric peroxynitrite assay
Peroxynitrite levels were measured in supernatants from aortic seg-
ments exposed to BCAA in the absence or presence of gp91dstat
and ML171 in DMEM‐F12 Ham for 24 hour as described above,
using the Fluorimetric Peroxynitrite Quantification kit (AAT Bioquest
Inc., Sunnyvale, CA, USA) according to the manufacturer's instruc-
tions. Standard curve was performed with a commercial peroxynitrite
(Sigma‐Aldrich). Fluorescence was quantified using a microtiter plate
fluorimeter (Ex/Em = 490/530 nm; Enspire, Perkin Elmer). Data were
normalized by vessel length and expressed as fold increase over the
control segment of the corresponding animal.
2.11 | Materials
BCAA were prepared as a mixture of leucine, isoleucine and valine at
0.2‐12 mmol/L each. BCAA, rapamycin, wortmannin, diphenyliodo-
nium chloride (DPI), L‐NAME, acetylcholine, phenylephrine and DEA‐
NO were obtained from Sigma‐Aldrich (Sigma Chemical Co., St. Louis,
MO, USA). DMEM‐F12 Ham medium and foetal bovine serum (FBS)
were also obtained from Sigma‐Aldrich. 5‐Aminoimidazole‐4‐carboxa-
mide‐1‐D‐ribofuranoside (AICAR) was purchased from Toronto
Research Chemicals (North York, Canada), while BAY‐11‐7082 and
ML171 were obtained from Calbiochem (La Jolla, CA). Mito‐TEMPO
was obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).
Celecoxib was a kind gift from Pfizer Inc. (Groton, CT, USA) and
gp91dstat was obtained from Anaspec (Fremont, CA). Wortmannin
and BAY‐11‐7082 were dissolved in DMSO. ML171 was dissolved in
75% ethanol. Further dilutions were in distilled water.
2.12 | Statistical analysis
Results are expressed as mean ± standard error (SEM). Statistical anal-
ysis was performed by using Mann‐Whitney test, or Kruskal‐Wallis test
for multiple comparison for in vitro experiments. Two‐way analysis of
variance followed by Bonferroni's post hoc test was used in ex vivo
vascular reactivity studies. A P < .05 was considered significant. Statis-
tical analysis was conducted using the PRISM5 statistical software.
3 | RESULTS
3.1 | BCAA stimulate the mTORC1 and AMPK
signalling pathways
BCAA produce several cell responses mainly via Akt/PI3K‐mTORC1
signalling pathway.22,25 We previously demonstrated that this axis
was activated under high concentrations of BCAA in PBMC.22 Thus,
we investigated the activation of Akt, mTORC1 and AMPK pathways
in ECs in vitro.
First, we performed a BCAA concentration‐response curve to
evaluate the phosphorylation of both pathways, using a concentra-
tion range from 0.2 to 12 mmol/L. The selected concentrations
range covered different pathological states including pathophysio-
logical concentrations found in obese and T2DM patients (0.2‐
0.7 mmol/L)9,10 and MSUD (2‐6 mmol/L)11,26 and in situations of
prolonged consumption as nutritional supplements (3‐6 mmol/L)
found in some individuals if consumed daily 6‐20 g BCAA for
2 months in 2 or 3 cycles per year or for uninterrupted period of
time.5,6 As shown in Figure 1A,B, BCAA induced phosphorylation
of mTORC1 and AMPK, with a maximal effect at 6 mmol/L after
1 hour of stimulation. Furthermore, AMPK induction caused by
BCAA mimicked the effect produced by AICAR (0.5 mmol/L), an
AMPK inducer used as a positive control (Figure 1C).
PI3K/Akt pathway is as an upstream activator of mTORC1 in dif-
ferent cell types.22,27,28 In ECs, BCAA promoted Akt phosphorylation
(Figure 1D). Interestingly, both the mTORC1 inhibitor rapamycin
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F IGURE 1 BCAA activate the PI3K/Akt‐mTORC1 and AMPK axis in endothelial cells. Effects of increasing BCAA concentrations (0.2‐
12 mmol/L, 1 h) on A, mTORC1 and B, AMPK activation on human endothelial cells (ECs). Effect of BCAA (6 mmol/L, 1 h) on human ECs pre‐
incubated 30 min with or without rapamycin (100 nmol/L) or AICAR (0.5 mmol/L) on C, AMPK, D, Akt and E, mTOR activation. F, eNOS mRNA
and protein expression in ECs. mTOR, AMPK and Akt activation and eNOS expression were calculated as ratios of phosphorylated proteins vs
corresponding total mTOR, GAPDH or α‐tubulin values and expressed as fold increase over control. For each panel, representative blots are
shown above. Data are expressed as mean ± SEM. *P < .05; **P < .01 vs Control vs Control (C); ≠P < .05 vs BCAA. n = 6
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(100 nmol/L) and the AMPK inducer AICAR decreased the BCAA‐
induced activation of Akt and mTORC1 (Figure 1D,E) suggesting that
in response to BCAA, AMPK is likely activated to counteract the
Akt/mTOR pathways and that there is a reciprocal relationship
between mTORC1 and Akt. Notably, BCAA also increased gene and
protein eNOS expression (Figure 1F).
3.2 | BCAA induce oxidative stress by activating
the mTORC1 pathway
We next investigated whether BCAA induce oxidative stress in
ECs and we focused on NADPH oxidase and mitochondria as
major sources of ROS at vascular level. As shown in Figure 2A‐C,
both NADPH oxidase activity and mitochondrial ROS production
were increased in the presence of BCAA (6 mmol/L) and this acti-
vation was abolished by rapamycin and AICAR. In addition, we
suggest the implication of 2 catalytic subunits of NADPH oxidase,
NOX‐1 and NOX‐2, as their gene expression was increased in the
presence of BCAA and also abolished by rapamycin and AICAR
(Figure 2D,E). Additionally, the BCAA‐induced NADPH oxidase
activation was abolished by the non‐selective inhibitor of NOX
(ML171, 0.5 μmol/L), by the selective NOX‐2 inhibitor gp91dstat
(5 μmol/L) and by the flavoprotein inhibitor DPI (10 μmol/L) (Fig-
ure 2A). As expected, the mitochondrial antioxidant (mito‐TEMPO,
F IGURE 2 BCAA induce ROS production via mTORC1. Effect of BCAA (6 mmol/L, 1 h) on human ECs pre‐incubated 30 min with or
without rapamycin (RAPA, 100 nmol/L), AICAR (0.5 mmol/L), DPI (10 μmol/L), ML171 (ML, 0.5 μmol/L), gp91dstat (dstat, 5 μmol/L), mito‐
TEMPO (MITO, 0.5 μmol/L) or BAY‐11‐7082 (BAY, 1 mmol/L) on A, NADPH oxidase activity and B, mitochondrial O2·−. C, Confocal microscopy
images showing mitochondrial O2
·− production using Mitosox (red) and DAPI for nuclei (blue). Effect of BCAA with or without rapamycin or
AICAR on gene expression of the NADPH oxidase subunits NOX‐1 (D) and NOX‐2 (E). Data are expressed as mean ± SEM. *P < .05;
**P < .01 vs Control vs Control (C). ≠P < .05 vs BCAA. n = 5‐7
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0.5 μmol/L) inhibited the BCAA‐induced production of mitochon-
drial ROS (Figure 2B). We then explored the involvement of other
pathways in the increase of ROS production by BCAA. Thus, the
inhibitor of the NF‐κB pathway (BAY‐11‐7082, 1 mmol/L) did not
affect NADPH oxidase activation or mitochondrial ROS production
(Figure 2A,B).
3.3 | BCAA trigger NF‐κB pro‐inflammatory
pathway in ECs
A positive relationship between oxidative stress generation and acti-
vation of the pro‐inflammatory NF‐κB pathway has been described
in different clinical conditions.29 One of the earliest events in NF‐κB
F IGURE 3 BCAA trigger NF‐κB pathway and pro‐inflammatory genes expression. Effect of BCAA (6 mmol/L, 1 h) on human ECs pre‐
incubated 30 min with or without rapamycin (RAPA), AICAR, ML171 (ML), gp91dstat (dstat), mito‐TEMPO (MITO) or BAY‐11‐7082 (BAY) on A,
p65 phosphorylation, B, DNA‐binding activity of p65 and on gene expression of C, E‐selectin and D, ICAM‐1. E, Effect of BCAA on iNOS
mRNA expression in ECs. Data are expressed as mean ± SEM. *P < .05; **P < .01 vs Control (C). ≠P < .05 vs BCAA. n = 6‐7
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pathway activation is the phosphorylation of p65 subunit. BCAA
(6 mmol/L) induced p65 activation and nuclear translocation and
binding to its DNA consensus sequence measured by DNA binding
activity assay in ECs (Figure 3A,B). The inhibition of mTORC1 by
rapamycin and the activation of AMPK by AICAR prevented the
effects of BCAA on NF‐κB activation (Figure 3A,B). Furthermore, the
increased p65 binding to its DNA consensus sequence elicited by
BCAA was dependent on the generation of mitochondrial ROS as it
was abolished in the presence of mito‐TEMPO, but not in presence
of NOXs inhibitors, ML171 and gp91dstat (Figure 3B).
Next, we evaluated several genes involved in cell adhesion and
migration regulated by NF‐κB such as E‐selectin and ICAM‐1.30 As
shown in Figure 3C,D, BCAA induced the expression of E‐Selectin
and ICAM‐1 in ECs. Both rapamycin and AICAR significantly
decreased gene expression similarly to that observed in the presence
of BAY‐11‐7082, used as control. The gene expression of the induci-
ble NO synthase isoform iNOS, another NF‐κB induced gene, was
also increased by BCAA (Figure 3E).
3.4 | BCAA induce leucocyte adhesion to
endothelium
The adhesion of monocytes to endothelial cells is considered one
of the initial events in endothelial dysfunction in vascular patholo-
gies.31,32 In our recent study, high levels of BCAA induced PBMC
migration22 and herein we observed increased expression of adhe-
sion molecules in ECs in response to BCAA. Thus, we next investi-
gated the effect of BCAA on PBMC adhesion to ECs. As shown in
Figure 4, BCAA significantly increased the adhesion of leucocytes
to ECs. This effect was prevented by rapamycin, AICAR and mito‐
TEMPO, but not by the NOXs inhibitors ML171 and gp91dstat,
wortmannin (PI3K inhibitor) or by the inhibitor of NF‐κB pathway
BAY‐11‐7082 (Figure 4) although a tendency towards decrease was
observed with wortmannin and BAY‐11‐7082.
3.5 | BCAA induce vasoconstrictor responses
through ROS production
The above results suggest that BCAA induce inflammation and
oxidative stress in ECs. To explore whether this might have an
impact on vascular reactivity, ex vivo experiments in aortic rings
were performed. In basal situation, BCAA triggered a minor vaso-
constrictor response of the aorta at very high concentrations
(>8 mmol/L) (Figure 5A,C). In contrast, when the aortic segments
were pre‐contracted with a submaximal concentration of phenyle-
phrine (0.3 μmol/L), BCAA contractile response was greatly
enhanced (Figure 5B,C). Pre‐treatment of the segments with
ML171, gp91dstat and mito‐TEMPO, decreased the BCAA‐induced
vasoconstriction (Figure 5C) without affecting phenylephrine pre‐
contraction (data not shown), supporting the contribution of ROS
from NADPH oxidase and mitochondria to BCAA‐induced vascular
contraction.
Endothelium modulates arterial responses to different vasocon-
strictors by releasing different vasodilator factors including NO. To
determine whether BCAA‐induced contractile response in basal
conditions was masked by NO, aortic segments were pre‐incu-
bated with the NOS inhibitor N‐nitro‐L‐arginine methyl ester (L‐
NAME) before BCAA concentration‐response curve. As shown in
Figure 5D, L‐NAME potentiated BCAA‐induced contractile
responses. Interestingly, in the presence of L‐NAME, BCAA‐
induced contractile responses were significantly diminished by
gp91‐dstat, ML171 and mito‐TEMPO, again suggesting that BCAA
induces vasoconstrictor responses through NADPH oxidase and
mitochondria‐derived ROS (Figure 5D). Additionally, COX‐2‐derived
contractile prostanoids could also participate in BCAA‐induced
contraction, as its selective inhibitor celecoxib decreased BCAA
contractile responses in the presence of L‐NAME (Figure 5D). A
possible effect due to osmotic pressure was excluded as the inac-
tive enantiomers D‐BCAA did not induce contractile responses in
aorta pre‐contracted with a submaximal concentration of phenyle-
phrine or when pre‐incubated with the NOS inhibitor L‐NAME
(data not shown).
To demonstrate the contribution of vascular smooth muscle cells
to BCAA‐induced contraction, we performed experiments where the
endothelium was mechanically removed. As shown in Figure 5E, in
endothelium‐denuded arteries pre‐contracted with phenylephrine
BCAA still induced a contractile response. However, this contractile
response was not observed neither in basal conditions nor in arteries
incubated with L‐NAME (Figure 5F), suggesting that endothelium‐
F IGURE 4 BCAA promote leucocytes
adhesion to endothelium. Effect of BCAA
(6 mmol/L, 1 h) on leucocytes adhesion to
ECs pre‐incubated with or without
rapamycin (RAPA), AICAR, wortmannin
(W), mito‐TEMPO (MITO), gp91dstat
(dstat), ML171 (ML) and BAY‐11‐7082
(BAY). Data are expressed as mean ± SEM.
***P < .001 vs Control (C). ≠P < .05;
≠≠P < .01 vs BCAA. n = 7
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dependent and ‐independent mechanisms are responsible for BCAA‐
induced contraction. They also suggest complex mechanisms of
smooth muscle contraction in response to BCAA as pre‐contraction
seems to be needed to achieve contraction.
3.6 | BCAA induce endothelial dysfunction through
ROS production
Oxidative stress is a well‐known promoter of endothelial dysfunc-
tion.33 We next evaluated the effect of long exposure (24 hour) to
F IGURE 5 BCAA induce vasoconstrictor responses through ROS and COX‐2‐derived contractile prostanoids. Representative tracings
showing the effect of BCAA (0.2‐10 mmol/L) on contraction of aortic segments in the absence (Control) (A) and in the presence of
phenylphrine (Phe) pre‐contraction (B). Quantification of contractile responses (red arrows) is shown in C, together with the effect of
gp91dstat, ML171 and mito‐TEMPO on concentration‐response curves to BCAA in aortic segments pre‐contracted with phenylephrine. D,
Effect of gp91dstat, ML171, mito‐TEMPO and celecoxib on BCAA‐induced contractile responses in aortic segments incubated with L‐NAME
(100 μmol/L, 30 min) without phenylephrine pre‐contraction. Concentration‐response curves to BCAA in aorta without endothelium (E‐) pre‐
contracted with phenylephrine (E) or incubated with L‐NAME without phenylephrine pre‐contraction (F). Data represent mean ± SEM.
***P < .001 vs Control. ≠P < .05; ≠≠P < .01; ≠≠≠P < .001 vs Phe or L‐NAME. n = 7‐10
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high concentrations of BCAA (6 mmol/L) in vascular responses. As
shown in Figure 6A,B, K+‐KHS and phenylephrine‐induced contractile
responses were greater in aortic segments incubated with BCAA
when compared to control and were both normalized by gp91dstat,
ML171 and mito‐TEMPO. BCAA also impaired the endothelium‐
dependent vasodilator responses induced by acetylcholine without
affecting endothelium‐independent relaxation to DEA‐NO (Fig-
ure 6C,D). Gp91dstat and ML171, but not mito‐TEMPO, normalized
endothelial function in BCAA‐incubated arteries (Figure 6C) suggest-
ing a role for NADPH oxidase derived ROS in BCAA‐induced
endothelial dysfunction. No significant effect of inhibitors was found
in control arteries (data not shown).
Excessive O2
·− can react with NO increasing peroxynitrite levels,
a potent oxidant that leads to the nitration of tyrosine residues in
tissue proteins. Accordingly, BCAA incubation increased aortic pro-
tein levels of nitrotyrosine and peroxynitrite formation that were
prevented by ML171 and gp91dstat (Figure 7A,B). Together, these
results suggest that BCAA impairs NO availability, rather than NO
signalling in vascular smooth muscle cells, by increasing ROS levels
mainly from NADPH oxidase.
4 | DISCUSSION
The main findings of our study are that high BCAA concentrations
can trigger oxidative stress and NF‐κB activation and inflammation in
ECs and in the vasculature thus likely contributing to the endothelial
dysfunction and cardiovascular disease frequently observed in differ-
ent pathological conditions associated to elevated BCAA levels.
There are few data about the relationship between elevated
BCAA plasma levels and inflammation. In MSUD patients, high BCAA
blood concentrations cause neurological damage associated with sus-
tained inflammation including elevated serum levels of IL‐1β, IL‐6
and IFN‐γ.34 In normoglycemic women, insulin resistance was associ-
ated with increased serum BCAA concentrations, down‐regulation of
mitochondrial energy metabolism and increased expression of inflam-
mation‐related genes (CCL2‐CCL5) in the adipose tissue.35 Finally,
our recent study demonstrated that elevated concentrations of
BCAA induced inflammation and oxidative stress in PBMC.22 Our
results in ECs further support the role of BCAA as mediators of
inflammation and ROS production and provide novel important infor-
mation that connects this systemic and local inflammatory milieu
with vascular damage. Thus, BCAA trigger ROS generation from
NADPH oxidases and mitochondria and also promote a pro‐inflam-
matory response characterized by increased NF‐κB activation and
subsequent up‐regulation of inflammatory molecules such as iNOS
and the adhesion molecules ICAM‐1 and E‐selectin, which facilitate
inflammatory cell migration22 and adhesion to ECs (present study).
Interestingly, mitochondrial ROS was responsible at least in part, for
the NF‐κB activation, but this transcription factor did not influence
ROS generation in response to BCAA, suggesting that alternative
pathways exist for BCAA‐induced oxidative stress. Our data are in
contrast with those published by D'Antona et al,36 showing
improved mitochondria biogenesis and decreased ROS production
together with increased antioxidant defenses in middle‐aged
(16 months old) mice supplemented with a BCAA enriched mixture
during 3 months. However, this approach is clearly different from
the acute effects of BCAA evaluated in our study. It is also impor-
tant to highlight that in this study,36 the levels of BCAA reached in
plasma after 3 months of BCAA supplementation are unknown and
this might be an important issue in the context of local exposure to
BCAA. Finally, HL‐1 cardiomyocytes were treated with a BCAA
enriched mixture that included 11 different amino acids which differ
from the 3 amino acids mixture used in our study.36
BCAA act as strong nutrient signals mainly activating mTORC1
to promote cell growth, proliferation, migration, inflammation and
oxidative stress in cancer cells27,37 and PBMC.22 We found that in
ECs BCAA also promoted concentration‐dependent phosphorylation
of mTORC1 and activation of Akt. Interestingly, mTORC1 was able
to modulate Akt activation, suggesting the existence of a cross‐talk
between both signalling pathways. More importantly, the effects of
BCAA on ROS generation, NF‐κB activation, inflammatory genes
expression and leucocytes adhesion to ECs, were blunted by rapa-
mycin. This highlights the pivotal role of mTORC1 in mediating pro‐
oxidant and pro‐inflammatory effects of BCAA on ECs, and it might
be in agreement with the role of the overactivation of Akt‐mTORC1
axis and the progression of the metabolic syndrome, future develop-
ment of T2DM and the associated endothelial cell activation and
endothelial dysfunction.37-39 The molecular mechanisms responsible
for the mTOR‐dependent activation of NOX and NF‐κB in response
to BCAA are unknown and this is a limitation of our study. However,
other authors have also found a role for mTOR in oxidative stress
generation40,41 or NF‐κB activation in response to different stimuli
or pathological conditions.42,43 Besides mTORC1, BCAA trigger sev-
eral signalling responses via the activation of AMPK, which plays a
role in cellular energy homoeostasis. We suggest that the upstream
activation of AMPK could be a tool to limit the activation of
mTORC1 in response to BCAA. This is in line with previous studies
in other cell types showing that AMPK can prevent mTORC1 activa-
tion.44 In turn, this mechanism might prevent, at least in part, down-
stream mTORC1‐induced ROS production, inflammation and cell
adhesion. In agreement, an AMPK activator AICAR, is able to
decrease these parameters in response to BCAA.
It is well accepted that unbalanced ROS production actively par-
ticipate in alterations of vascular tone associated with various dis-
eases, such as hypertension, diabetes or atherosclerosis.33,45 The
major sources of ROS at vascular level are NADPH oxidase and
mitochondria.46-48 Our data show for the first time that BCAA pro-
duce functional effects on the vascular wall. Thus, although BCAA
induced minor vasoconstrictor responses per se, they led to strong
contractile responses in arteries that were pre‐contracted with sub-
maximal concentrations of phenylephrine, suggesting that some
degree of vascular tone, probably as found in physiological condi-
tions, is needed for BCAA to induce contraction. This might also
have pathophysiological consequences particularly in the context of
vascular diseases where vascular hypercontractility is frequently
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observed. Moreover, BCAA enhanced K+‐KHS and phenylephrine
contractions after overnight incubation. The mechanisms responsible
for the augmented vascular contractility in response to BCAA war-
rant further investigation. However, both the contractile responses
induced by BCAA and the BCAA‐induced enhancement of K+‐KHS
and phenylephrine responses were diminished by mito‐TEMPO and
NADPH oxidase inhibitors, suggesting a role for mitochondria and
NADPH‐derived ROS in BCAA‐induced contraction. Additionally,
BCAA might act directly in vascular smooth muscle cells as sug-
gested by the fact that in endothelium‐denuded vessels BCAA still
induced contraction and, as mentioned, in BCAA‐incubated arteries,
responses to a depolarizing K+‐KHS stimulus, were significantly
enhanced. Mechanisms responsible of this direct effect of BCAA in
vascular smooth muscle cell are also unknown. However, Ca2+‐sensi-
tization mechanisms cannot be discarded as ROS have been reported
to activate different proteins involved in that process.49,50
It is well known that NO is a powerful vasodilator released toni-
cally and in response to agonists such as acetylcholine. NOS blockade
with L‐NAME unmasked contractile responses to BCAA in resting
arteries that were inhibited by different antioxidants such as ML‐171,
gp91dstat and mito‐TEMPO, again demonstrating the potential of
BCAA to induced oxidative stress with functional impact. We also
demonstrated the contribution of COX‐2 to BCAA‐induced contrac-
tion as the selective COX‐2 inhibitor celecoxib also abolished BCAA
F IGURE 6 BCAA induce endothelial dysfunction through ROS. A, Contraction to depolarizing solution of high KCl (K+‐KHS) in arteries
incubated with BCAA (6 mmol/L, 24 h) in the absence or presence of different antioxidants: gp91dstat, ML171, and mito‐TEMPO.
Concentration‐response curves to phenylephrine (Phe) (B), acetylcholine (ACh) (C) and diethylamine NONOate (DEA‐NO) (D) in aortic segments
incubated with BCAA in the absence or presence of gp91dstat, ML171 and mito‐TEMPO. Data represent mean ± SEM. *P < .05; ***P < .001
vs Control; ≠P < .05; ≠≠P < .01; ≠≠≠P < .001 vs BCAA.
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contractile responses in L‐NAME‐incubated arteries. Whether this
effect was due to COX‐2‐derived prostanoids or to the reciprocal
relationship between ROS and COX‐2 suggested previously,51-54 is
unknown. More importantly, our data demonstrate that this exces-
sive O2
·− likely reacts with NO leading to increased peroxynitrite
formation and nitrosylated proteins, decreased NO availability and
in turn, endothelium dysfunction. The fact that NADPH oxidase
inhibitors, although not mitochondrial antioxidants, improved
endothelial‐dependent relaxation confirms this hypothesis. Of note,
a dysfunctional endothelium with diminished NO levels might be
unable to buffer BCAA‐induced ROS production, thus amplifying
BCAA ability to contract the arteries further perpetuating the vas-
cular damage.
One limitation of our study is that we cannot know exactly what
is the main source of ROS in response to BCAA in our experimental
paradigm, and we can only affirm that BCAA increases the activation
of NADPH oxidase and mitochondrial ROS production that in turn
affect different processes including NF‐κB activation, cell adhesion
and vascular function. The reasons for the different contribution of
mitochondria and NADPH oxidase to the different parameters are
unknown and probably rely on a complex regulation of each
response or a possible reciprocal relationship between both sources
as described earlier.54,55 Finally, other sources of O2
·− such as the
uncoupled eNOS, COX‐2 or xanthine oxidase among others, cannot
be excluded.
Our data provide a proof‐of‐concept of the potential harmful
effect of BCAA in the vascular endothelium. However, the physiologi-
cal relevance of the concentrations of BCAA and times of exposure
used in the present study remain to be established. Thus, the pro‐oxi-
dant and inflammatory effects of BCAA were observed at concentra-
tions that could be reached in MSUD7,27 or in daily BCAA
supplementation in sportsmen,5,6 but higher than those found in
patients suffering from obesity or diabetes.8,9 However, it is important
to highlight that lower concentrations of BCAA (0.5‐2 mmol/L) already
increased vascular contraction which might add physiological rele-
vance. On the other hand, chronic exposure to moderately elevated
BCAA levels added to hyperglycaemia and pro‐inflammatory condi-
tions decrease the threshold of mTOR phosphorylation and increase
ROS formation in PBMC27,37 and we cannot discard that this mecha-
nism might be also operating in endothelial cells.
Together, our findings provide mechanistic and functional evi-
dence linking elevated levels of BCAA and endothelial dysfunction.
We demonstrate that elevated BCAA levels produce inflammation
and oxidative stress in endothelial cells via mTORC1 pathway, there-
fore facilitating inflammatory cells adhesion. In turn, this pro‐oxidant
and inflammatory milieu facilitate vascular hypercontractility and
F IGURE 7 BCAA induce nitrotyrosine expression and increase peroxynitrite levels. Effect of BCAA (6 mmol/L, 24 h) pre‐incubated 30 min
with or without ML171 and gp91dstat (dstat) on A, protein nitrosylation levels in aortic sections and B, peroxinytrite levels measured in
supernatants from aortic segments. Data are expressed as mean ± SEM. *P < .05 vs Control (C). ≠P < .05 vs BCAA. n = 3‐5
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diminished endothelium‐dependent relaxation (Figure 8). If chronic
exposure to these BCAA is achieved, these early events might even-
tually converge in atherosclerosis and other cardiovascular complica-
tions.
ACKNOWLEDGEMENTS
Olha Zhenyukh was the recipient of a fellowship from Fundación
Conchita Rábago.
CONFLICT OF INTEREST
No conflicts of interest relevant to this article were reported.
ETHICS STATEMENT
The procedure was approved by the Research Ethics Committee of
Instituto de Investigaciones Sanitarias Fundación Jiménez Díaz and
Universidad Autónoma de Madrid.
AUTHOR CONTRIBUTIONS
Z.O., B.A.M. and E.J. conceived the experiments and analysed data.
Z.O., B.A.M. and E.J. wrote the manuscript. Z.O., G.A.M and R.D.R.
performed the experiments and analysed data. E.V., S.M., R.O.M. and
M.S. contributed to the discussion and reviewed and edited the
manuscript.
F IGURE 8 Scheme demonstrating the possible relationship between branched‐chain amino acids (BCAA), reactive oxygen species (ROS) and
inflammation and its putative role in endothelial dysfunction and cardiovascular diseases. The influx of BCAA into endothelial cells is mediated
by binding to specific nutrient transporters. In cytoplasm, BCAA activate PI3K‐Akt/mTORC1 and AMPK signalling pathways. The BCAA‐
dependent activation of these pathways seems to induce NADPH oxidase activation, mitochondrial oxidative stress and nuclear transcription
factor‐κB (NF‐κB) leading to increased production of ROS and pro‐inflammatory factors. BCAA‐induced oxidative and pro‐inflammatory status
promote leucocytes migration and adhesion to the endothelium. In addition, ROS derived from mitochondria or through mechanisms involving
NOX‐1 and NOX‐2 subunits of NADPH oxidase could reduce NO availability. These events, in turn, would induce endothelial dysfunction and
vasoconstriction. All together, these vascular alterations might contribute to the development of cardiovascular diseases in clinical conditions
associated with elevated levels of BCAA
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